Management of Recurrent Acute Lymphoblastic Leukemia with T-Cell Engagement: CAR T, BiTEs, and Beyond

Recent advances in cancer immunotherapy have led to novel treatment options in the setting of relapsed or refractory acute lymphoblastic leukemia (R/R ALL).

Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Pediatric Acute Lymphoblastic Leukemia (ALL)
Informing clinicians about emerging strategies for pediatric ALL management will shed light on new prognostic markers that could be targeted in pediatric ALL to enhance therapeutic efficacy and minimize short- and long-term treatment-related toxicities.
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Pediatric Acute Lymphoblastic Leukemia (ALL)

Emerging Strategies for Pediatric ALL Management

NCCN Guidelines® Insights - Acute Lymphoblastic Leukemia, Version 1.2019

Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy.

Recorded Presentations from the NCCN 2018 Congress Webinar Series: Acute Leukemia

During 2017, the US Food and Drug Administration (FDA) approved three new AML drugs and brought back a fourth that had been withdrawn in 2010.

Recorded Presentation from the NCCN 2018 Congress Webinar Series: Acute Leukemia - Monitoring Minimal Residual Disease in Leukemia and Impact on Treatment

The goal of this activity is to ensure that members of the multidisciplinary oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to apply the new standards of care for patients with an acute leukemia.

Recorded Presentation from the NCCN 2018 Congress Webinar Series: Acute Leukemia - Refractory Acute Lymphoblastic Leukemia Management: New Insights

The goal of this activity is to ensure that members of the multidisciplinary oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to apply the new standards of care for patients with an acute leukemia.

Recorded Presentation from the NCCN 2018 Congress Webinar Series: Acute Leukemia - Impact of Changing Molecular Landscape on Leukemia Management

The goal of this activity is to ensure that members of the multidisciplinary oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to apply the new standards of care for patients with an acute leukemia.

CAR T-Cell Therapy: Recent Advances and Future Considerations
NCCN organized a task force consisting of a multidisciplinary panel of experts in oncology, cancer center administration, and health policy, which met for the first time in March 2018. This webinar describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves.
Keynote Session: CAR T-cell Therapy - Focus on Leukemia

Chimeric antigen receptor (CAR) T-cell therapy is an emerging immune-based therapy used in cancer treatment. It has demonstrated significant impact in the management of hematologic malignancies, including B-cell acute lymphoblastic leukemia (B-ALL).

Pages

Subscribe to RSS - Acute Lymphoblastic Leukemia